

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: Unknown)
)
Examiner: Unknown)
)
Applicants: Woulfe, et al.)
)
Application Number: Unknown)
)
Filed: December 3, 2003)
)
For: ENGINEERED FAB' FRAGMENT)
ANTI-TUMOR NECROSIS FACTOR)
ALPHA IN COMBINATION WITH)
DISEASE MODIFYING ANTI-)
RHEUMATIC DRUGS)

CERTIFICATE OF MAILING

Express Mail No.: EV 322135025 US

Date of Deposit: 12-5-03

I certify that the accompanying paper is being deposited with the United States Postal Service and sent "Via Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

William Asher

Typed or Printed Name:

William Asher

Signature

Mail Stop Patent Application
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Information Disclosure Statement

As listed on the accompanying form PTO-1449, applicants submit with this information disclosure statement copies of the indicated references, which applicants believe may be material to the examination of the above-identified application, and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made, an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Further, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.

**Identification Of Time Of Filing The
Information Disclosure Statement**

- ☒ This Information Disclosure Statement is being filed within three months of the filing date of the national application.
- ☐ This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in §1.491 in an international application.
- ☐ This Information Disclosure Statement is being filed before the mailing date of the First Office Action on the merits.
- ☐ This Information Disclosure Statement is being filed after three months of the filing date of the national application or after three months of the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Accompanying this transmittal is:

- ☐ a statement specified in 37 CFR § 1.97(e); or
- ☐ a fee set forth in 37 CFR § 1.17(p)
- ☐ This Information Disclosure Statement is being filed after the mailing date of a final action under § 1.113, or a notice of allowance under § 1.311 but before the payment of the issue fee.

Accompanying this transmittal is:

1. a statement as specified in 37 CFR § 1.97(e); and
2. a fee set forth in 37 CFR § 1.17(p)

Statement For Information Disclosure Statement 37 CFR 1.97(E)
(Only if Required Above)

I, the person signing below, hereby state that:

- ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
37 CFR § 1.97(e)(1); or

- ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in the counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR § 1.97(e)(2).

Translations of Foreign Documents


This Information Disclosure Statement includes no patents that are written in Non-English languages.

Fee Payment

- ☐ attached is a check in the amount of \$ _____
- ☐ charge Deposit Account No. 07-0153
in the amount. \$ _____
- A duplicate of this request is attached.**

Applicants believe that no additional fees are due for the filing of this IDS. However, if any additional fees are due, or any overpayments have been made, please charge, or credit, Deposit Account No. 07-0153.

Dated: December 5, 2003


Carol M. Nielsen
Attorney for Assignee
Registration No.: 37,676
Gardere Wynne Sewell LLP
1000 Louisiana Street, Suite 3400
Houston, Texas 77002-5007
Phone: (713) 276-5383
Fax: (713) 276-6383
Email: cnielson@gardere.com

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 122294-1010		Application Number Unknown		
				Applicant(s) W ulfe, et al.				
				Filing Date December 5, 2003		Group Art Unit Unknown		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5,656,272	8/12/97	Le, et al.	424	133.1	2/4/94	
		5,741,488	4/21/98	Feldman, et al.	424	154.1	5/3/95	
		6,270,766 B1	8/7/01	Feldman, et al.	424	145.1	8/1/96	
		6,455,275 B1	9/24/02	Axel, et al.	435	69.1	6/7/95	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
		WO 94/08619	4/28/94	United Kingdom	39	395	YES	NO
		WO 95/09652	4/13/95	United Kingdom	39	395		
		WO 98/25971	6/18/98	United Kingdom	16	00		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		New Anti-Rheumatoid Drugs Bring Hope to Thousands; Arthritis Research Campaign 2002; pp. 1-2; January 1999.						
		FDA Approves Drug for Rheumatoid Arthritis Combination Treatment; News Release; ArthritisSupport.com; Pro Health, Inc.; http://www.arthritisupport.com ; pp. 1-4; 2000.						
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								